<DOC>
	<DOCNO>NCT02672111</DOCNO>
	<brief_summary>Open-label multi-center , 12-month safety study , consistent standard practice long-term safety study . This one year safety study utilize CAM2038 q1w ( weekly ) q4w ( monthly ) 3 phase : Screening , Treatment , Follow-up .</brief_summary>
	<brief_title>Long-Term Safety Study Buprenorphine ( CAM2038 ) Adult Outpatients With Opioid Use Disorder</brief_title>
	<detailed_description>Open-label multi-center , 12-month safety study , consistent standard practice long-term safety study . This one year safety study utilize CAM2038 q1w ( weekly ) q4w ( monthly ) 3 phase : Screening , Treatment , Follow-up . Patients currently take sublingual ( SL ) BPN ( weekly monthly prescription visit ) individual actively seek BPN treatment yet begin treatment regimen , may eligible study . Following Screening , qualify subject meet inclusion criterion meet exclusion criterion initiate either CAM2038 q1w q4w , base current treatment status ( qualified subject currently SL BPN seek BPN treatment ) . Qualified subject initiate transition CAM2038 q1w q4w follow : Initiation BPN treatment - initiate CAM2038 q1w Currently receive SL BPN treatment - transfer correspond CAM2038 q1w q4w dose</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Subject must provide write informed consent prior conduct studyrelated procedure . 2 . Male female , 1865 year age , inclusive . ( Taiwan : 2065 year age , inclusive ) 3 . Female subject childbearing potential must willing use highly effective method contraception entire study ( Screening Visit FollowUp Visit ) ( Section 9.1.6 ) . 4 . Current diagnosis moderate severe opioid use disorder ( DSMV ) past medical history opioid use disorder currently treat SL BPN . 5 . Considered Investigator good candidate BPN treatment , base medical psychosocial history . 6 . Subjects must meet one follow criterion BPN treatment history : Voluntarily seek treatment opioid use disorder ( currently BPN treatment least last 60 day seek BPN treatment ) , ; Currently SL BPN treatment . 1 . Current diagnosis Acquired Immune Deficiency Syndrome ( AIDS ) . 2 . Current diagnosis chronic pain require opioids treatment . 3 . Current DSMV diagnosis moderate severe substance use disorder ( include alcohol ) opioids , caffeine nicotine currently treat primary substance use disorder . 4 . Recent history current evidence suicidal ideation active suicidal behavior base Columbia Suicide Severity Rating Scale ( CSSRS ) ( `` Yes '' response question 4 5 ) . 5 . Pregnant lactate plan become pregnant study . 6 . Hypersensitivity allergy naloxone ( subject receive SL BPX test dose ) , BPN excipients CAM2038 . 7 . Requires chronic use agent strong inhibitor inducer cytochrome P450 3A4 ( CYP 3A4 ) azole antifungal ( e.g. , ketoconazole ) , macrolide antibiotic ( e.g. , clarithromycin ) , protease inhibitor ( e.g. , ritonavir , indinavir , saquinavir ) . 8 . Hepatitis , unless stable treatment , discretion Investigator . 9 . Any pending legal action could prohibit participation compliance study . 10 . Exposure investigational drug within 4 week prior Screening . 11 . Aspartate aminotransferase ( AST ) level ≥3 X upper limit normal , alanine aminotransferase ( ALT ) , level ≥ 3 X upper limit normal , total bilirubin ≥ 1.5 X upper limit normal , creatinine ≥ 1.5 X upper limit normal Screening laboratory assessment , clinically significant laboratory abnormality , opinion Investigator may prevent subject safely participate study . 12 . Participants history risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) ECG demonstrate Fridericia 's correct QT interval ( QTcF ) &gt; 450 msec male QTcF &gt; 470 female screen . 13 . Significant symptom , medical condition , circumstance , opinion Investigator , would preclude compliance protocol , adequate cooperation study obtain informed consent , may prevent subject safely participate study . This include , limited , subject attention deficit hyperactivity disorder receive central stimulant ( e.g . methylphenidate central stimulant ) , well subject severe respiratory insufficiency , respiratory depression , airway obstruction , gastrointestinal motility disorder , severe hepatic insufficiency , plan surgery prior treatment monoamine oxidase inhibitor . 14 . Is employee Investigator trial site , direct involvement propose trial study direction Investigator trial site , family member employee Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>